Table 1. Demographics of stage I ovarian cancer.
| All | LVSI (+) | LVSI (-) | P-value | |
|---|---|---|---|---|
| Cases | n=434 | n=76 (17.5%) | n=358 (82.5%) | |
|
| ||||
| Age | 53.9 (±11.9) | 55.7 (±12.0) | 53.5 (±11.8) | 0.15 |
|
| ||||
| Race | 0.75 | |||
| Caucasian | 10 (2.3%) | 2 (2.6%) | 8 (2.2%) | |
| African American | 3 (0.7%) | 1 (1.3%) | 2 (0.6%) | |
| Asian | 421 (97.0%) | 73 (96.1%) | 348 (94.2%) | |
|
| ||||
| Histology | 0.042 | |||
| High-grade serous | 36 (8.3%) | 8 (10.5%) | 28 (7.8%) | |
| Low grade serous | 21 (4.8%) | 3 (3.9%) | 18 (5.0%) | |
| Clear cell | 179 (41.2%) | 41 (53.9%) | 138 (38.5%) | |
| Endometrioid | 112 (25.8%) | 9 (11.8%) | 103 (28.8%) | |
| Mucinous | 67 (15.4%) | 11 (14.5%) | 56 (15.6%) | |
| Mixed | 16 (3.7%) | 4 (5.3%) | 12 (3.4%) | |
| Other | 3 (0.7%) | 0 | 3 (0.8%) | |
|
| ||||
| Stage | 0.044 | |||
| IA | 136 (31.3%) | 16 (21.1%) | 120 (33.5%) | |
| IB | 6 (1.4%) | 0 | 6 (1.7%) | |
| IC | 292 (67.3%) | 60 (78.9%) | 232 (64.8%) | |
|
| ||||
| Stage IC sub-category | 0.24 | |||
| Capsule involvement | 86 (29.5%) | 18 (30.0%) | 68 (29.3%) | |
| Intraoperative capsule rupture | 163 (55.8%) | 34 (56.7%) | 130 (56.0%) | |
| Malignant cytology† | 29 (9.9%) | 8 (13.3%) | 21 (9.1%) | |
| Rupture + cytology | 14 (4.8%) | 0 | 13 (5.6%) | |
|
| ||||
| Grade‡ | 0.17 | |||
| 1 | 155 (61.5%) | 17 (48.6%) | 138 (63.6%) | |
| 2 | 63 (25.0%) | 13 (37.1%) | 50 (23.0%) | |
| 3 | 34 (13.5%) | 5 (14.3%) | 29 (13.4%) | |
|
| ||||
| Postoperative chemotherapy | 0.006 | |||
| No | 110 (25.9%) | 10 (13.2%) | 100 (28.7%) | |
| Yes | 315 (74.1%) | 66 (86.8%) | 249 (71.3%) | |
|
| ||||
| Chemotherapy cycle | 6 (1-12) | 6 (1-8) | 6 (1-12) | 0.27 |
|
| ||||
| Chemotherapy type | 0.67* | |||
| Carboplatin + paclitaxel | 200 (63.5%) | 40 (60.6%) | 160 (60.6%) | |
| Carboplatin + docetaxel | 42 (13.3%) | 5 (7.6%) | 37 (14.9%) | |
| Irrinotecan + mitomycin C | 16 (5.1%) | 2 (3.0%) | 14 (5.6%) | |
| Irrinotecan + cisplatin | 15 (4.8%) | 2 (3.0%) | 13 (5.2%) | |
| CB-EC | 10 (3.2%) | 7 (10.6%) | 3 (1.2%) | |
| Others** | 32 (10.2%) | 10 (15.2%) | 22 (8.8%) | |
|
| ||||
| Slide No. for ovarian tumor | 5 (1-19) | 6 (1-19) | 5 (1-17) | 0.009 |
Number (%) per group [all, LVSI (+) or LVSI (-)], mean (±SD), or mean (range) is shown. P-values for comparison of LVSI (+) and LVSI (-).
*
P-value for carboplatin + paclitaxel versus others.
†
cytology for ascites or washing.
‡
No routine grading for clear cell type, and 3 cases from other histology types missed grading.
**
15 different regimens.
Abbreviations: LVSI, lymphovascular space invasion; and intraope, intraoperative; CB-EC, carboplatin + epirubicin + cyclophosphamide.